Serendipity Ixora

Serendipity Ixora identifies, invests in, and develops companies that commercialize products based on leading academic research. Their fields of investments are Advanced Materials, Medtech, Cleantech, and Biotech. However, they do not restrict themselves to any particular industrial sector. They typically invest at the early stages of development and consider themselves as long-term owners. 
Type VC
Website sdip.se

Investment info

Invests in
Product or prototype
Go to market
Growth and expansion
Investment range
€ 50 - 100K
€ 100 - 500K
€ 0,5 - 1M
€ 1 - 5M
€ > 5M
Primary markets
Consumer, Companies, Marketplace
Investing in countries
Denmark, Finland, Norway, Sweden

Focus areas

Consumer Goods
Consumer Goods
Energy & Greentech
Energy & Greentech
Healthcare & Life Science
Healthcare & Life Science
IT & Software
IT & Software
See all 6 focus areas

Investments

P

Premune

X

Xbrane

N

Nanologica

O

OrganoClick

Invests in SDGs

sdg

More about Serendipity Ixora

Experience

Ixora was founded in 2004. Their portfolio currently consists of 10 companies. The business focus is to identify, invest and develop growth companies with products and services with global market potential. Each company is developed according to Serendipity's commercialization models. A key component of their work is the combination of well-functioning management teams with complementary skills in product development, business development, marketing, and sales. They are not necessarily exit-driven if the company is making revenue.

 

How much do they invest?

Ixora's management team is the largest shareholder in Ixora and takes an active role in the business operations as well as in the strategic management of the portfolio companies. They can invest alongside other investment companies. Their investment varies, but they can invest around $10 M in portfolio companies. 

 

How do they work?

Prior to new investments, companies are evaluated by market potential, scalability, and distinct competitive advantage in the form of deep niches, high differentiation, strong leadership, and the ability to deliver high margins.

 

This makes a difference to them

Common ground for all portfolio companies is the ability to combine disruptive technologies with strong teams aiming for global market opportunities. As such, all companies are heading for scalable applications with high differentiation and the ability to deliver high margins. Each individual holding is expected to have the ability to, over time, generate a ROE in excess of 20 percent. 

 

Key People

Saeid Esmaeilzadeh – Chairman and Co-founder Saeid a serial entrepreneur having established and managed a range of innovative technology companies within several industries. He is an adjunct professor in material chemistry at Stockholm University and received his Ph.D. in 2000. He served as the CEO between 2010 and 2015. LinkedIn

Amin Omrani - CEO Amin joined Serendipity in 2009 and has served as COO and VP of Business Development. He has co-founded several companies within Serendipity and serves on several of the company’s boards. Amin has his educational background in industrial engineering and demand chain management. LinkedIn

 

Startups they funded

Premune, Xbrane, Nanologica, and OrganoClick.

How to contact

Sign up to get access to contact details or log in if you already have an account.

This profile is currently managed by The Hub, .